Durvalumab After Sequential Chemoradiotherapy Is Safe for Stage III, Unresectable NSCLC: Results From Phase 2 PACIFIC-6 Trial. Zhao B, Li H, Wu J, Ma W, et al. J Thorac Oncol 2023;18:e1-e2.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zhao B, Li H, Wu J, Ma W, et al. Durvalumab After Sequential Chemoradiotherapy Is Safe for Stage III, Unresectable NSCLC: Results From Phase 2 PACIFIC-6 Trial. J Thorac Oncol 2023;18:e1-e2.
PMID: 36543435